Cosmo pharmaceuticals

At Cosmo, we are committed to improve peoples lives by developing products that address unmet medical needs in the fields of gastroenterology, dermatology and healthtech.

Investors

Latest News

06 Dec 2023

Cosmo confirms full redemption in cash of €175m Convertible Bonds

Read More
10 Oct 2023

Cosmo Announces Submission of Winlevi® to the European Medicines Agency (EMA)

Read More
02 Oct 2023

Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries

Read More

Upcoming Events

16 Jan 2024

27th ODDO BHF Forum 2024

Add to Outlook
15 Feb 2024

Preliminary 2023 Results

Add to Outlook
21 Mar 2024

Full Year Results 2023

Add to Outlook

Latest presentation

01 Nov 2023
November Investor Presentation

Therapeutic Focus

Cosmo’s therapeutic focus is on the treatment of gastrointestinal diseases (including IBD, colonic infections and colorectal cancer – CRC), increase the effectiveness of endoscopic examinations and to treat persistent skin conditions, like acne, and androgenetic alopecia, that have a long-term physical and emotional impact on lives and self-esteem.

Find out more

Our Mission

To improve people’s lives by developing products that address unmet medical needs in the fields of gastroenterology, dermatology and healthtech.

Find out more

Manufacturing

We provide services related to the production of pharmaceutical products as: assessment of manufacturing processes, technology transfer, evaluation of pharmaceutical product stability, testing and release to the market and drafting of the necessary documentation for pharmaceutical products’ registration.

Find out more